Summary

The global cardiovascular devices market is USD 77.71 billion in 2024 and is projected to reach USD 110.39 billion by 2029, at a CAGR of 7.3 % during the forecast period.

The growth of the cardiovascular devices market is driven by several key factors, most notably the increasing prevalence of cardiovascular diseases (CVD) worldwide, advancements in minimally invasive procedures, and growing demand for improved patient outcomes and lastly shifting preference to remote monitoring. As rates of heart disease rise, the need for effective monitoring and treatments such as angioplasty, stenting, and valve replacements also increases where these devices are implemented. Technological innovations, including the development of drug-eluting stents, bioresorbable scaffolds and occluders, and advanced imaging technologies, have enabled safer and more precise procedures, which contribute to the market’s growth.

“Based on the product type, the the cardiac imaging and diagnostic device segment holds a significant share the cardiovascular devices market.”
Cardiac imaging and diagnostic devices include a range of medical technologies used to visualize the heart and assess its functions, enabling the detection, diagnosis, and monitoring of heart diseases. These devices provide detailed images of the heart's structure, blood flow, and electrical activity. The cardiac imaging and diagnostic devices segment is the one to grow at the highest rate in the cardiovascular devices market. This is due to growing global burden of cardiovascular diseases, advancing imaging technologies, rising importance of early diagnosis, and precision medicine. As it is CVDs remain the leading cause of mortality throughout the world, demands increasingly accurate and non-invasive diagnostic tools. Advancements like real-time 3D echocardiography, cardiac MRI, and AI-assisted imaging solutions also significantly enhance the diagnostic efficiency concerning the quality of care for patients and lead to the adoption of such devices among healthcare providers. Apart from this, prevalence of chronic diseases, which increases the risk for heart-related issues, further presses upon continuous cardiac monitoring and the demand for early detection. Government initiatives and healthcare reimbursement policies in the advanced as well as emerging markets drive the adoption of advanced imaging devices. Telehealth capabilities and portable diagnostic devices also make it more accessible, supporting broader market penetration.

“The Coronary artery disease segment holds the largest market share in cardiovascular devices market.”
Coronary heart disease occurs when plaque (atherosclerosis) builds up inside the coronary arteries, that feed blood to the heart muscle, and narrows or blocks them. Thereby, breathlessness or angina may result from heart muscle not receiving enough oxygen rich blood. In extreme cases, heart attack or myocardial infarction may occur due to a total blockage of the coronary artery.Some of the major causes for CAD include an unhealthy lifestyle, including a diet full of saturated fats, lack of exercise, and smoking, which cause damage to the arteries over time. Other factors that contribute to this condition include hypertension, high cholesterol levels, diabetes, and obesity, all of which further the development of plaque. Genetic disposition, age, and chronic stress also add to the development of CAD due to their general impact on the heart and blood vessels. The increasing incidence of the above factors coupled with hightened awareness among the popuation regarding therse diseases would aid in market growth.

“Based on the end user, Others segment is expected to grow by the significant CAGR in the cardiovascular devices market.
The "others" segment, which includes applications like general health checkup, fitness, and wellness monitoring, intraoperative monitoring, and post-op care, is growing the fastest in the cardiovascular device market. This is because of increased focus on preventive care, personalized medicine, and holistic patient care. With the ever-growing awareness on the importance of regular cardiovascular monitoring, there are growing demands for wearable and connected devices which measure parameters including heart rate, blood pressure, and ECG among healthy patients and chronic diseases patients. Advanced intraoperative monitoring equipment during surgery helps assess patients' hearts real time in safety for patient comfort and best surgical results. Additionally, monitoring devices post-surgery will help track the recovery, early detection of complications, and minimize hospital readmission rates. Integration of AI and IoT into these devices improves the accuracy of data, patient engagement, and clinician decision-making. On the other hand, adoption of telehealth and remote patient monitoring technologies is growing and allows the continuation of care outside the clinical setting.

“Asia Pacific to grow with the highest CAGR in the Cardiovascular devices market during the forecast period.”
The Asia-Pacific region is also expected to experience maximum growth in the cardiovascular devices market in the next few years due to several key factors. Growth is driven by an increasingly aging population, the growing prevalence of cardiovascular diseases, and increased adoption of minimally invasive procedures, especially in countries such as China, Japan, and India. Increased healthcare expenses and development of health infrastructure promote the availability of high-end interventional cardiology services throughout the region.

The break up of the profile of primary participants in the cardiovascular devices market:
• By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%
• By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%.
• By Region: North America - 40%, Europe – 30%, APAC –20%, Latin America – 5%,Middle East & Africa–5%

Key players in the cardiovascular devices market
Some of the prominent players operating in the cardiovascular devices market include Medtronic Plc (Ireland), Abbott Laboratories (US), Boston Scientific Corporation (US), Terumo Corporation (Japan), GE Healthcare Technologies, Inc. (US), Edward Lifesciences Corporation (US), Siemens Healthineers AG (Germany), Johnson & Johnson (US), Baxter International Inc (US), B. Braun SE (Germany), Getinge AB (Sweden), Koninklijke Philips N.V. (Netherlands), Lepu Medical Technology (Beijing) Co., Ltd (China), Nihon Kohden Corporation (Japan), MicroPort Scientific Corporation (China), Japan Lifeline Co., Ltd. (Japan), AngioDynamics, Inc.(US), LifeTech Scientific Corporation (China), Artivion Inc (US), Sahajanand Medical Technologies Limited (India), OrbusNeich Medical Group Holdings Limited (China), BPL Medical Technologies (India), BiotroniK. (Germany),), W.L. Gore & Associates, Inc (US), Canon medical systems corporation (Japan), Picard Medical Company (US).
Research Coverage:
The report analyzes the cardiovascular devices market and aims at estimating the market size and future growth potential of this market based on various segments such as products, indication and end user. The report also includes a product portfolio matrix of various cardiovascular device technologies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall cardiovascular devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights into the following pointers:
• Of Analysis of key drivers (The increase in prevalence of cardiovascular diseases, The increasing preference for minimally invasive techniques, Technological Advancements Fueling Innovation in Cardiovascular Devices, Rise in Remote Patient Monitoring), restraints (Stringent regulatory guidelines for product approval, Lack of skilled Cardiovascular Healthcare professionals), opportunities (Projected Growth in the Elderly Population, Emerging Opportunities in Biodegradable Cardiovascular Devices) and challenges (Product failures and recalls, Adverse Effects and Complications with usage of implantable cardiovascular devices).
• Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global cardiovascular devicesmarket.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global cardiovascular devices market
• Market Development: Comprehensive information on the lucrative emerging markets by product, indication and enduser.
• Market Diversification: Exhaustive information about new product or product enhancements, growing geographies, recent developments, and investments in the global cardiovascular devices market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of product and services, and capacities of the major competitors in the global cardiovascular devices market.

ページTOPに戻る

Table of Contents

A1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.3 MARKET SCOPE 35
1.3.1 MARKET SEGMENTATION 35
1.3.2 INCLUSIONS & EXCLUSIONS 36
1.3.3 YEARS CONSIDERED 36
1.3.4 CURRENCY CONSIDERED 37
1.4 STAKEHOLDERS 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
2.1.1 SECONDARY DATA 39
2.1.1.1 Key data from secondary sources 40
2.1.2 PRIMARY DATA 40
2.1.2.1 Key data from primary sources 42
2.1.2.2 Key industry insights 42
2.2 MARKET SIZE ESTIMATION 43
2.3 GROWTH FORECAST 45
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 48
2.5 MARKET RANKING ANALYSIS 49
2.6 STUDY ASSUMPTIONS 49
2.7 RESEARCH LIMITATIONS 49
2.7.1 METHODOLOGY-RELATED LIMITATIONS 49
2.7.2 SCOPE-RELATED LIMITATIONS 50
2.8 RISK ASSESSMENT 50
3 EXECUTIVE SUMMARY 51
4 PREMIUM INSIGHTS 55
4.1 CARDIOVASCULAR DEVICES MARKET OVERVIEW 55
4.2 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET,
BY END USER AND COUNTRY (2023) 56
4.3 CARDIOVASCULAR DEVICES MARKET: REGIONAL MIX, 2024–2029 (USD MILLION) 57
5 MARKET OVERVIEW 58
5.1 INTRODUCTION 58
5.2 MARKET DYNAMICS 58
5.2.1 DRIVERS 59
5.2.1.1 Rising incidence of cardiovascular diseases 59
5.2.1.2 Increasing accessibility to advanced high-performance devices 59
5.2.1.3 Growing preference for minimally invasive surgeries 60
5.2.1.4 Rising technological advancements in cardiovascular devices 60
5.2.1.5 Increasing trend of remote patient monitoring 60
5.2.2 RESTRAINTS 61
5.2.2.1 Stringent regulatory guidelines for product approval 61
5.2.2.2 Shortage of skilled cardiac health professionals 62
5.2.3 OPPORTUNITIES 62
5.2.3.1 Rising geriatric population and increasing uptake of CVD devices 62
5.2.3.2 Emergence of biodegradable cardiovascular devices 62
5.2.4 CHALLENGES 63
5.2.4.1 Product recalls & failures 63
5.2.4.2 Complications associated with implantable devices 63
5.3 INDUSTRY TRENDS 64
5.3.1 MINIMALLY INVASIVE PROCEDURES 65
5.3.2 WEARABLE TECHNOLOGY AND REMOTE MONITORING 65
5.3.3 PERSONALIZED MEDICINE 65
5.4 TECHNOLOGY ANALYSIS 66
5.4.1 KEY TECHNOLOGIES 66
5.4.1.1 Transcatheter aortic valve replacement (TAVR) 66
5.4.1.2 Cardiac mapping systems 66
5.4.1.3 3D-printed cardiovascular devices 67
5.4.2 COMPLEMENTARY TECHNOLOGIES 67
5.4.2.1 Robotic-assisted surgeries 67
5.4.2.2 Advanced catheter systems 67
5.4.2.3 Imaging technologies 68
5.4.3 ADJACENT TECHNOLOGIES 68
5.4.3.1 Regenerative medicine 68
5.4.3.2 Biomaterials & nanotechnology 68
5.4.3.3 Big data & cloud computing 69
5.5 PORTER’S FIVE FORCE ANALYSIS 69
5.5.1 THREAT OF NEW ENTRANTS 69
5.5.2 BARGAINING POWER OF SUPPLIERS 70
5.5.3 BARGAINING POWER OF BUYERS 70
5.5.4 THREAT OF SUBSTITUTES 70
5.5.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.6 REGULATORY LANDSCAPE 71
5.6.1 REGULATORY ANALYSIS 71
5.6.1.1 North America 71
5.6.1.1.1 US 71
5.6.1.1.2 Canada 72
5.6.1.2 Europe 72
5.6.1.3 Asia Pacific 72
5.6.1.4 Latin America 73
5.6.1.5 Middle East & Africa 73
5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
5.7 PATENT ANALYSIS 76
5.7.1 PATENT PUBLICATION TRENDS IN CARDIOVASCULAR DEVICES MARKET 76
5.7.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 77
5.8 TRADE ANALYSIS 80
5.9 PRICING ANALYSIS 80
5.10 KEY CONFERENCES & EVENTS, 2024−2025 82
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 83
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 83
5.11.2 BUYING CRITERIA 84
5.12 UNMET NEEDS/END-USER EXPECTATIONS IN CARDIOVASCULAR DEVICES MARKET 85
5.13 IMPACT OF AI/GENERATIVE AI ON CARDIOVASCULAR DEVICES MARKET 86
5.14 ECOSYSTEM ANALYSIS 86
5.15 CASE STUDY ANALYSIS 88
5.15.1 CASE STUDY 1: EVALUATION OF TAVR SYSTEM 88
5.15.2 CASE STUDY 2: SAFETY & EFFICACY ASSESSMENT OF WATCHMAN DEVICE IN ATRIAL FIBRILLATION 89
5.15.3 CASE STUDY 3: PERFORMANCE ANALYSIS OF MITRACLIP FOR THE TREATMENT OF MITRAL REGURGITATION 90
5.16 SUPPLY CHAIN ANALYSIS 90
5.17 ADJACENT MARKET ANALYSIS 92
5.17.1 CARDIAC MONITORING AND RHYTHM MANAGEMENT DEVICES MARKET 92
5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 93
5.19 CARDIOVASCULAR DEVICES MARKET: INVESTMENT & FUNDING SCENARIO 94
5.20 R&D PIPELINE ANALYSIS 95
6 CARDIOVASCULAR DEVICES MARKET, BY PRODUCT 96
6.1 INTRODUCTION 97
6.2 CARDIAC IMAGING & DIAGNOSTIC DEVICES 98
6.2.1 ECG DEVICES 100
6.2.1.1 Low costs and expanding applications to fuel market 100
6.2.2 CARDIAC ULTRASOUND IMAGING 101
6.2.2.1 Growing preference towards minimally invasive techniques to boost demand 101
6.2.3 CARDIAC COMPUTERIZED TOMOGRAPHY (CT) SCANNERS 103
6.2.3.1 Increasing preference over other diagnostic imaging methods to drive market 103
 
6.2.4 CARDIAC MAGNETIC RESONANCE IMAGING (MRI) 104
6.2.4.1 Increasing incidence of cardiac diseases to fuel uptake 104
6.2.5 NUCLEAR CARDIOLOGY SYSTEMS 106
6.2.5.1 Ability to assess tissue functionality and heart physiology to support market growth 106
6.2.6 CARDIAC DIAGNOSTIC CATHETERS 107
6.2.6.1 Rising focus on catheterization procedures to fuel market 107
6.3 CARDIAC RHYTHM MANAGEMENT DEVICES 109
6.3.1 PACEMAKERS 111
6.3.1.1 Growing availability of leadless and MRI-safe devices to boost demand 111
6.3.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD) 112
6.3.2.1 Increasing prevalence of arrhythmias to drive market 112
6.3.3 CARDIAC RESYNCHRONIZATION THERAPY (CRT) DEVICES 114
6.3.3.1 Ability to reduce fatigue and associated heart failure symptoms to boost demand 114
6.4 INTERVENTIONAL CARDIOLOGY DEVICES 115
6.4.1 CORONARY STENTS 118
6.4.1.1 Technological advancements in stents to fuel uptake 118
6.4.2 HEART VALVE DEVICES 120
6.4.2.1 Increasing prevalence of valve stenosis and regurgitation to fuel market 120
6.4.3 CLOSURE DEVICES 121
6.4.3.1 Utilization of self-expandable materials to drive market 121
6.4.4 SURGICAL CATHETERS 122
6.4.4.1 Rising adoption of angioplasty procedures to support market growth 122
6.4.5 GUIDEWIRES 124
6.4.5.1 Rising uptake in PCI procedures to drive market 124
6.4.6 OTHER INTERVENTIONAL CARDIOLOGY DEVICES 125
6.5 CARDIAC ASSIST DEVICES 127
6.5.1 VENTRICULAR ASSIST DEVICES 129
6.5.1.1 Rising incidence of heart failure to boost market 129
6.5.2 INTRA-AORTIC BALLOON PUMPS (IABP) 130
6.5.2.1 Product recalls to restrain market 130
6.5.3 TOTAL ARTIFICIAL HEART (TAH) 131
6.5.3.1 Growing product pipeline to fuel market 131
6.5.4 IMPELLA DEVICES 133
6.5.4.1 Increasing utility in high-risk procedures to support market growth 133
6.6 ELECTROPHYSIOLOGY DEVICES 134
6.6.1 EP CATHETERS 136
6.6.1.1 Rising incidence of chronic heart conditions to drive market 136
 
6.6.2 ABLATION SYSTEMS 137
6.6.2.1 Increasing utilization of radiofrequency ablation procedures to support market growth 137
6.6.3 3D MAPPING SYSTEM 139
6.6.3.1 Development of alternative technologies to hinder market 139
6.7 EXTERNAL SUPPORT DEVICES 140
6.7.1 EXTERNAL DEFIBRILLATORS 142
6.7.1.1 Adoption of user-friendly AEDs to fuel market 142
6.7.2 EXTERNAL PACEMAKERS 143
6.7.2.1 Technological advancements in leadless & implantable pacemakers to restrain market 143
6.7.3 CARDIAC COMPRESSION DEVICES 145
6.7.3.1 Reduced CPR rate to restrain market 145
6.8 MONITORING DEVICES 146
6.8.1 BLOOD PRESSURE MONITORS 148
6.8.1.1 Portability and ease of use to fuel market 148
6.8.2 PULSE OXIMETERS 149
6.8.2.1 Increasing adoption of OTC devices in home care settings to propel market 149
6.8.3 IMPLANTABLE CARDIAC MONITORS (ICM) 151
6.8.3.1 Growing focus on RPM to support market 151
7 CARDIOVASCULAR DEVICES MARKET, BY INDICATION 153
7.1 INTRODUCTION 154
7.2 CORONARY ARTERY DISEASE 155
7.2.1 ANGINA PECTORIS 156
7.2.1.1 Growing adoption of implantable monitors and ECG devices for treatment to drive market 156
7.2.2 MYOCARDIAL INFARCTION 158
7.2.2.1 Increasing demand for stents in acute cases to fuel market 158
7.3 ARRHYTHMIAS 159
7.3.1 TACHYCARDIA 161
7.3.1.1 Rising cardiac electrophysiology procedures to drive market 161
7.3.2 BRADYCARDIA 162
7.3.2.1 Rising incidence of OSA to support market growth 162
7.4 STRUCTURAL HEART DISEASE 164
7.4.1 VALVULAR HEART DISEASE 165
7.4.1.1 Rising risks of aortic stenosis to drive market 165
7.4.2 CONGENITAL HEART DISEASE 167
7.4.2.1 Potential for new therapies to fuel uptake 167
7.4.3 CARDIOMYOPATHY 168
7.4.3.1 Uptake of ICDs to drive market 168
 
7.4.4 CONGESTIVE HEART FAILURE 170
7.4.4.1 Growth in geriatric population to fuel market 170
7.5 INFLAMMATORY HEART DISEASE 171
7.5.1 PERICARDITIS 173
7.5.1.1 Increasing incidence due to COVID-19 to support market growth 173
7.5.2 MYOCARDITIS 175
7.5.2.1 Increasing prevalence of autoimmune diseases to support market growth 175
7.5.3 ENDOCARDITIS 176
7.5.3.1 Focus on echocardiography for clinical evaluation to drive market 176
7.6 OTHER CARDIOVASCULAR INDICATIONS 178
8 CARDIOVASCULAR DEVICES MARKET, BY END USER 180
8.1 INTRODUCTION 181
8.2 HOSPITALS & CLINCS 182
8.2.1 HIGH PURCHASING POWER OF HOSPITALS AND RISING NUMBER OF CARDIOVASCULAR PROCEDURES TO DRIVE MARKET 182
8.3 DIAGNOSTIC LABORATORIES 184
8.3.1 RISING FOCUS ON TECHNOLOGICALLY ADVANCED DIAGNOSTIC INSTRUMENTS TO SUPPORT MARKET GROWTH 184
8.4 AMBULATORY SURGERY CENTERS 185
8.4.1 INCREASING DEMAND FOR OUTPATIENT CARE AND RPM SERVICES TO PROPEL MARKET 185
8.5 OTHER END USERS 187
9 CARDIOVASCULAR DEVICES MARKET, BY REGION 189
9.1 INTRODUCTION 190
9.2 NORTH AMERICA 191
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 191
9.2.2 US 205
9.2.2.1 Increasing cases of obesity due to sedentary lifestyles to propel market 205
9.2.3 CANADA 216
9.2.3.1 Increasing funding for CVD research to support market growth 216
9.3 EUROPE 227
9.3.1 INCREASING PRODUCT APPROVALS FOR ADVANCED CARDIOVASCULAR DEVICES TO DRIVE MARKET 227
9.3.2 MACROECONOMIC OUTLOOK FOR EUROPE 227
9.4 ASIA PACIFIC 240
9.4.1 LARGE TARGET PATIENT POPULATION AND INCREASING INCIDENCE OF CVD TO PROPEL MARKET 240
9.4.2 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 240
 
9.5 LATIN AMERICA 252
9.5.1 BURDEN OF CONGENITAL HEART DISEASES TO DRIVE MARKET 252
9.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 253
9.6 MIDDLE EAST & AFRICA 265
9.6.1 RISING HEALTHCARE EXPENDITURE TO SUPPORT MARKET GROWTH 265
9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 265
10 COMPETITIVE LANDSCAPE 279
10.1 OVERVIEW 279
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 279
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CARDIOVASCULAR DEVICES MARKET 280
10.3 REVENUE ANALYSIS 282
10.4 MARKET SHARE ANALYSIS 283
10.4.1 RANKING OF KEY MARKET PLAYERS, 2023 285
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 285
10.5.1 STARS 285
10.5.2 EMERGING LEADERS 285
10.5.3 PERVASIVE PLAYERS 286
10.5.4 PARTICIPANTS 286
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 287
10.5.5.1 Company footprint 287
10.5.5.2 Region footprint 288
10.5.5.3 Product footprint 289
10.5.5.4 Indication footprint 290
10.5.5.5 End-user footprint 291
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 292
10.6.1 PROGRESSIVE COMPANIES 292
10.6.2 RESPONSIVE COMPANIES 292
10.6.3 DYNAMIC COMPANIES 292
10.6.4 STARTING BLOCKS 292
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 294
10.7 COMPANY VALUATION & FINANCIAL METRICS 295
10.7.1 COMPANY VALUATION 295
10.7.2 FINANCIAL METRICS 296
10.8 BRAND/PRODUCT COMPARISON 296
10.9 COMPETITIVE SCENARIO 297
10.9.1 PRODUCT LAUNCHES & APPROVALS 297
10.9.2 DEALS 298
10.9.3 EXPANSIONS 299
10.9.4 OTHER DEVELOPMENTS 299
 
11 COMPANY PROFILES 300
11.1 KEY PLAYERS 300
11.1.1 MEDTRONIC 300
11.1.1.1 Business overview 300
11.1.1.2 Products offered 301
11.1.1.3 Recent developments 309
11.1.1.3.1 Product launches & approvals 309
11.1.1.3.2 Deals 310
11.1.1.4 MnM view 311
11.1.1.4.1 Key strengths 311
11.1.1.4.2 Strategic choices 311
11.1.1.4.3 Weaknesses & competitive threats 311
11.1.2 ABBOTT LABORATORIES 312
11.1.2.1 Business overview 312
11.1.2.2 Products offered 313
11.1.2.3 Recent developments 321
11.1.2.3.1 Product launches & approvals 321
11.1.2.3.2 Deals 323
11.1.2.4 MnM view 323
11.1.2.4.1 Key strengths 323
11.1.2.4.2 Strategic choices 324
11.1.2.4.3 Weaknesses & competitive threats 324
11.1.3 BOSTON SCIENTIFIC CORPORATION 325
11.1.3.1 Business overview 325
11.1.3.2 Products offered 326
11.1.3.3 Recent developments 333
11.1.3.3.1 Product launches & approvals 333
11.1.3.3.2 Deals 333
11.1.3.4 MnM view 335
11.1.3.4.1 Key strengths 335
11.1.3.4.2 Strategic choices 335
11.1.3.4.3 Weaknesses & competitive threats 335
11.1.4 GE HEALTHCARE 336
11.1.4.1 Business overview 336
11.1.4.2 Products offered 337
11.1.4.3 Recent developments 339
11.1.4.3.1 Product launches & approvals 339
11.1.4.3.2 Deals 340
11.1.4.4 MnM view 341
11.1.4.4.1 Key strengths 341
11.1.4.4.2 Strategic choices 341
11.1.4.4.3 Weaknesses & competitive threats 341
11.1.5 TERUMO CORPORATION 342
11.1.5.1 Business overview 342
11.1.5.2 Products offered 343
11.1.5.3 Recent developments 347
11.1.5.3.1 Product launches & approvals 347
11.1.5.4 MnM view 348
11.1.5.4.1 Key strengths 348
11.1.5.4.2 Strategic choices 348
11.1.5.4.3 Weaknesses & competitive threats 348
11.1.6 EDWARDS LIFESCIENCES CORPORATION 349
11.1.6.1 Business overview 349
11.1.6.2 Products offered 350
11.1.6.3 Recent developments 352
11.1.6.3.1 Product launches & approvals 352
11.1.6.3.2 Deals 353
11.1.7 SIEMENS HEALTHINEERS AG 354
11.1.7.1 Business overview 354
11.1.7.2 Products offered 355
11.1.7.3 Recent developments 357
11.1.7.3.1 Product launches & approvals 357
11.1.8 JOHNSON AND JOHNSON SERVICES, INC. 358
11.1.8.1 Business overview 358
11.1.8.2 Products offered 359
11.1.8.3 Recent developments 362
11.1.8.3.1 Product launches & approvals 362
11.1.8.3.2 Deals 363
11.1.9 SAHAJANAND MEDICAL TECHNOLOGIES LIMITED 364
11.1.9.1 Business overview 364
11.1.9.2 Products offered 364
11.1.10 BAXTER INTERNATIONAL INC 366
11.1.10.1 Business overview 366
11.1.10.2 Products offered 367
11.1.10.3 Recent developments 369
11.1.10.3.1 Deals 369
11.1.11 ARTIVION, INC. 370
11.1.11.1 Business overview 370
11.1.11.2 Products offered 371
11.1.12 GETINGE AB 373
11.1.12.1 Business overview 373
11.1.12.2 Products offered 374
11.1.12.3 Recent developments 375
11.1.12.3.1 Product launches & approvals 375
11.1.12.3.2 Deals 375
11.1.13 KONINKLIJKE PHILIPS N.V. 376
11.1.13.1 Business overview 376
11.1.13.2 Products offered 377
11.1.13.3 Recent developments 379
11.1.13.3.1 Product launches & approvals 379
11.1.14 NIHON KOHDEN CORPORATION 380
11.1.14.1 Business overview 380
11.1.14.2 Products offered 381
11.1.15 BIOTRONIK SE & CO.KG. 383
11.1.15.1 Business overview 383
11.1.15.2 Products offered 383
11.1.16 LEPU MEDICAL TECHNOLOGY(BEIJING) CO., LTD. 388
11.1.16.1 Business overview 388
11.1.16.2 Products offered 388
11.1.16.3 Recent developments 394
11.1.16.3.1 Product launches & approvals 394
11.1.17 MICROPORT SCIENTIFIC CORPORATION 396
11.1.17.1 Business overview 396
11.1.17.2 Products offered 397
11.1.17.3 Recent developments 401
11.1.17.3.1 Product launches & approvals 401
11.1.18 ANGIODYNAMICS INC. 403
11.1.18.1 Business overview 403
11.1.18.2 Products offered 405
11.1.19 JAPAN LIFELINE CO., LTD. 406
11.1.19.1 Business overview 406
11.1.19.2 Products offered 407
11.1.19.3 Recent developments 410
11.1.19.3.1 Product launches & approvals 410
11.1.20 W.L. GORE & ASSOCIATES 411
11.1.20.1 Business overview 411
11.1.20.2 Products offered 411
11.1.21 B. BRAUN SE 412
11.1.21.1 Business overview 412
11.1.21.2 Products offered 414
11.2 OTHER PLAYERS 415
11.2.1 CANON MEDICAL SYSTEMS CORPORATION 415
11.2.2 PICARD MEDICAL COMPANY 416
11.2.3 BPL MEDICAL TECHNOLOGIES PVT LTD 417
11.2.4 LIFETECH SCIENTIFIC CORPORATION 418
11.2.5 ORBUSNEICH MEDICAL GROUP HOLDINGS LIMITED 419
12 APPENDIX 420
12.1 DISCUSSION GUIDE 420
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 425
12.3 CUSTOMIZATION OPTIONS 427
12.4 RELATED REPORTS 427
12.5 AUTHOR DETAILS 428